Pages that link to "Q34415843"
Jump to navigation
Jump to search
The following pages link to Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene (Q34415843):
Displaying 50 items.
- Obesity and cancer (Q21558465) (← links)
- Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis (Q29615683) (← links)
- Histological evaluation of AMPK signalling in primary breast cancer (Q33499119) (← links)
- Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration (Q33807145) (← links)
- Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. (Q34058540) (← links)
- The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression (Q34127212) (← links)
- Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells (Q34286341) (← links)
- Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. (Q34431310) (← links)
- Orlistat-associated adverse effects and drug interactions: a critical review (Q34586250) (← links)
- Efficacy of massage therapy on pain and dysfunction in patients with neck pain: a systematic review and meta-analysis. (Q35138738) (← links)
- Metabolic alterations and targeted therapies in prostate cancer (Q35401667) (← links)
- Fatty acid synthase as a potential therapeutic target in cancer (Q35401716) (← links)
- Metformin: multi-faceted protection against cancer (Q35764409) (← links)
- Obesity and HER 2 overexpression: a common factor for poor prognosis of breast cancer (Q36493977) (← links)
- Potential use of humanized antibodies in the treatment of breast cancer. (Q36532110) (← links)
- Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer (Q36563827) (← links)
- Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines (Q36664997) (← links)
- Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine (Q36908847) (← links)
- Loss of fatty acid synthase inhibits the "HER2-PI3K/Akt axis" activity and malignant phenotype of Caco-2 cells (Q36945535) (← links)
- Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy. (Q37013406) (← links)
- The prince and the pauper. A tale of anticancer targeted agents (Q37042365) (← links)
- Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death (Q37095819) (← links)
- Fatty Acids and Breast Cancer: Make Them on Site or Have Them Delivered (Q38722530) (← links)
- Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy (Q39298900) (← links)
- Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis. (Q39661482) (← links)
- Fatty acid synthesis is a therapeutic target in human liposarcoma (Q39717889) (← links)
- Comparative docking of dual conformations in human fatty acid synthase thioesterase domain reveals potential binding cavity for virtual screening of ligands (Q40688083) (← links)
- Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells (Q42120578) (← links)
- Total synthesis of tetrahydrolipstatin and stereoisomers via a highly regio- and diastereoselective carbonylation of epoxyhomoallylic alcohols. (Q42147079) (← links)
- The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas (Q42511450) (← links)
- Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells (Q42776481) (← links)
- Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells (Q45056589) (← links)
- Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines (Q46547178) (← links)
- Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells (Q46850551) (← links)
- Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA). (Q48221452) (← links)
- Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer (Q49244460) (← links)
- Fatty acid synthase (FASN) as a therapeutic target in breast cancer. (Q50044384) (← links)
- De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer. (Q51807216) (← links)
- The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model. (Q52724728) (← links)
- Ratiometric Raman imaging reveals the new anti-cancer potential of lipid targeting drugs (Q57138111) (← links)
- [Obesity and cancer] (Q57147001) (← links)
- Orlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance (Q59125766) (← links)
- Characterization of Tetrahydrolipstatin and Stereoderivatives on the Inhibition of Essential Mycobacterium tuberculosis Lipid Esterases (Q63369533) (← links)
- Membrane Lipid Composition: Effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues. (Q64981840) (← links)
- Identifying and targeting cancer-specific metabolism with network-based drug target prediction. (Q64993423) (← links)
- Evaluation of the antiviral activity of orlistat (tetrahydrolipstatin) against dengue virus, Japanese encephalitis virus, Zika virus and chikungunya virus (Q84957829) (← links)
- WITHDRAWN: Membrane-lipid therapy: A historical perspective of membrane-targeted therapies-From lipid bilayer structure to the pathophysiological regulation of cells (Q88007813) (← links)
- Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin (Q88061375) (← links)
- Reprogramming of fatty acid metabolism in cancer (Q91826302) (← links)
- Targeting FASN in Breast Cancer and the Discovery of Promising Inhibitors from Natural Products Derived from Traditional Chinese Medicine (Q95823234) (← links)